



PROJECT JELLYFISH

Investment Teaser

Patented, first-of-its-kind jellyfish collagen platform targeting brain, gut, immunity, and healthy-aging applications, supported by emerging human clinical data and an asset-light commercialization model.

U.S.-based developer of science-backed nutraceutical ingredients with 30+ years of formulation expertise and global ingredient relationships.

Seeking a capital or strategic partner to accelerate launch, advertising and scale-up of a differentiated marine collagen ingredient and adjacent proprietary formulations.

INDUSTRY

**Nutraceuticals /
Functional Ingredients**

HEADQUARTERS

U.S.-Based

CAPITAL SOUGHT

\$1.0–1.5M

EXIT HORIZON

3–5 Years

COMPANY OVERVIEW

- Built by a U.S. nutraceutical innovator with 30+ years of science-backed ingredient development across aging, joint, cardio, immune and brain health.
- Lead asset is a patented hydrolyzed jellyfish collagen with types I, II and V peptides, all 20 amino acids, minerals and calcium-binding proteins.
- Asset-light model combines proprietary IP, formulation know-how and partner-led manufacturing/distribution to accelerate commercialization.

TRANSACTION OVERVIEW

- Seeking \$1.0–1.5M of growth capital, strategic investment or acquisition consideration to commercialize the lead ingredient platform.
- Proceeds earmarked for advertising, launch activation, production scale-up, initial inventory and continued market education.
- Management targets a 3–5 year exit horizon and plans further diligence with manufacturing and commercialization stakeholders.

INVESTMENT HIGHLIGHTS

01 Patented, first-of-its-kind platform

U.S. and China patent protection; management reports three issued patents overall, supporting a differentiated marine-collagen moat.

02 Human clinical proof-of-concept

Published 2025 open-label pilot reported a 12% Neurocognitive Index improvement plus significant memory and executive-function gains after eight weeks.

03 Scalable launch model

Ingredient can be formulated into supplements, foods and beverages; Atlas adds U.S. oral-solid, fluid-bed drying and on-site analytical capabilities.

04 Multiple monetization and exit paths

Opportunity spans bulk ingredient sales, branded/private-label products, licensing and strategic sale to larger nutrition, ingredient or CDMO buyers.

SELECTED OPPORTUNITY SNAPSHOT

Metric	Current	12–18 Mo.	3–5 Yr. Path
IP estate	3 issued patents*	Extend formulation moat	License / strategic sale
Clinical support	2025 pilot published	Follow-on studies / KOLs	Premium cognition position
Manufacturing	Atlas CDMO identified	Launch inventory scale-up	Volume-driven leverage
Market access	Early partner traction	U.S. launch + promotion	Broader global rollout
Capital need	\$1.0–1.5M sought	Marketing + working capital	Exit / recap path

*Management has not yet provided historical financial statements; operating snapshot shown in lieu of a financial table.

PRODUCT / SERVICE OVERVIEW

- Patented hydrolyzed jellyfish collagen ingredient with types I, II and V peptides, minerals and all 20 amino acids.
- Flexible formulation across capsules, tablets, powders, beverages and functional foods for cognitive, gut-immune, mood and nutri-beauty positioning.
- Pipeline includes a confidential DNA-targeted formulation and adjacent branded/private-label concepts.

CUSTOMER PROFILE

- Target customers include nutraceutical brands, private-label marketers, wellness distributors and strategic ingredient partners seeking differentiated actives.
- Buyer groups span product development, brand, sourcing and e-commerce teams; revenue can come from bulk ingredient or finished-product sales.
- Existing industry relationships and early partner activity provide a base for repeat orders once launch marketing is funded.

END MARKETS & FOOTPRINT

- Addressable categories include cognitive wellness, healthy aging, beauty-from-within, gut health and functional foods / beverages.
- U.S.-based opportunity with prior international partner commercialization, supporting multi-channel domestic and export expansion.
- White space includes DTC, practitioner channels, private label, licensing and adjacent formulations built on the same IP.

KEY DIFFERENTIATORS

01 First-of-its-kind ingredient

Patented jellyfish collagen offers a nutrient profile not found in conventional collagen sources.

02 Published pilot validation

Recent human data showed gains in Neurocognitive Index improvement, memory and executive function after 8 weeks.

03 Asset-light scale path

U.S. CDMO, Atlas's capabilities can accelerate launch without major in-house capex.

04 Multiple value-creation levers

Growth paths include ingredient supply, finished products, licensing, geography and strategic M&A.